PFKFB4抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Raji cell, Primary antibody: P04663(PFKFB4 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P04663(PFKFB4 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P04663(PFKFB4 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

PFKFB4 (6-phosphofructo-2-kinase/fructose-2.6-biphosphatase 4) is a bifunctional enzyme that regulates glycolytic flux by controlling intracellular levels of fructose-2.6-bisphosphate (F2.6BP), a potent allosteric activator of phosphofructokinase-1 (PFK-1). As a member of the PFKFB family, PFKFB4 uniquely balances kinase and phosphatase activities, favoring F2.6BP synthesis under certain conditions. It plays critical roles in metabolic adaptation, particularly in cancer cells, where it supports aerobic glycolysis (Warburg effect) and redox homeostasis by modulating NADPH production. PFKFB4 is also implicated in stress responses, including hypoxia and endoplasmic reticulum stress, influencing cell survival and proliferation.

PFKFB4 antibodies are essential tools for studying its expression, localization, and function in diverse biological contexts. These antibodies enable detection via Western blotting, immunohistochemistry, and immunofluorescence, aiding research on metabolic dysregulation in tumors, metabolic disorders, and other diseases. Commercially available PFKFB4 antibodies are typically raised against specific epitopes, with validation in knockout models or siRNA-mediated knockdown to confirm specificity. Recent studies highlight PFKFB4 as a therapeutic target, particularly in cancers reliant on glycolytic metabolism, driving demand for reliable antibodies in preclinical research. Understanding PFKFB4's role through antibody-based assays continues to advance insights into metabolic reprogramming and disease mechanisms.